AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02864251
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT02864251
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT03478488
Drug: KN035 plus Gemcitabine & oxaliplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: KN035 a programmed death ligand immune check inhibitor Per Investigator decision
Trial: NCT03478488
Drug: Gemcitabine & oxaliplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The standard of care for the patients with unresectable/metastatic biliary tract cancer
Trial: NCT01053819
Drug: etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.
Trial: NCT01165255
Drug: 2. Exposure to bupropion outside the first trimester comparison cohort
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to bupropion outside the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. The comparison cohort (bupropion exposure outside the first trimester) included women whose bupropion exposure occurred at least one month before the estimated date of conception and women whose bupropion exposure occurred after the first trimester, but before delivery. This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy) during the period outside the first trimester.
Trial: NCT01165255
Drug: 1. Exposure to bupropion during the first trimester
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exposure to bupropion during the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. Infants were classified according to maternal exposure to bupropion during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy). A woman was considered exposed in the first trimester if there was at least one dispensing of bupropion during the first trimester of pregnancy.
Trial: NCT04356690
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4.
Trial: NCT04059679
Drug: Rivaroxaban 2.5 Mg Oral Tablet
RxNorm normalized name: rivaroxaban 2.5 MG Oral Tablet
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)
Trial: NCT04059679
Drug: Aspirin 81 mg
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EC aspirin 81 mg qd
Trial: NCT00333866
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600mg/day
Trial: NCT00333866
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 450mg/day
Trial: NCT00333866
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300mg/day
Trial: NCT03508817
Drug: Atropine Sulfate 0.01% Eye Drops
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atropine eye drop in study eye once nightly for two years.
Trial: NCT03762109
Drug: Dantrolene
RxNorm normalized name: Dantrolene
DrugBank: Dantrolene (DB01219)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: muscle relaxant
Trial: NCT00259077
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03847818
Drug: Pyrotinib+Trastuzumab+Docetaxel+Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Pyrotinib Pyrotinib: 400mg orally daily~Drug: Trastuzumab Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;~Drug: Docetaxel Docetaxel: 75mg/m2 for a total of 6 cycles~Drug: Carboplatin Carboplatin: AUC=5 or 6 for a total of 6 cycles
Trial: NCT00050011
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received Letrozole 2.5 mg daily.
Trial: NCT02426892
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.
Trial: NCT00323518
Drug: velafermin
RxNorm normalized name: VELAFERMIN
DrugBank: Velafermin (DB06493)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously as 100mL single dose over 15 minutes on day 1
Trial: NCT03925246
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (Opdivo) is a potent human monoclonal antibody (mAb) of the IgG4 isotype designed to directly block the interaction between Programmed Cell Death 1 (PD-1) and its ligands, Programmed Death Ligand 1 (PD-L1) and PD-L2.~Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 (+/- 2 days) weeks for 8 cycles (4 months), followed by a dose of 480 mg administered by a 60 minutes intravenous infusion every 4 weeks (+/-3 days) (beginning at cycle 9) for a total therapy duration of 1 year (maximum 16 cycles of treatment) or until progression, death, unacceptable toxicity.
Trial: NCT02624479
Drug: Sodium thiosulfate
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration of thiosulfate
Trial: NCT04507269
Drug: VIR-2218
RxNorm normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIR-2218 given by subcutaneous injection
Trial: NCT03615768
Drug: Adapalene Gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Differin 0.1% Gel, applied nightly for 12 weeks
Trial: NCT04235062
Drug: Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 2-hour of infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution will be given following completion of the first 3-hour urine collection period: 0.5 liter infused over 10 min followed by 0.5 liter infused over 1 hour 50 minutes.
Trial: NCT04235062
Drug: Intravenous Bolus Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following completion of the second 3-hour urine collection period and after the second set of blood and urine samples are obtained, 40 mg of furosemide will be given as an IV bolus.
Trial: NCT03378635
Drug: Dasiglucagon
RxNorm normalized name: Dasiglucagon
DrugBank: Dasiglucagon (DB15226)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucagon analog
Trial: NCT04451330
Drug: Trifarotene cream
RxNorm normalized name: trifarotene
DrugBank: Trifarotene (DB12808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trifarotene 50 mcg/g cream applied topically once daily on face for 12 weeks.
Trial: NCT03378635
Drug: GlucaGen
RxNorm normalized name: GlucaGen
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Native glucagon
Trial: NCT00648713
Drug: Terbinafine Hydrochloride Tablets 250 mg
RxNorm normalized name: Terbinafine Hydrochloride
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg, single dose fed
Trial: NCT00313521
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00027300
Drug: Natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks.
Trial: NCT03726879
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered as per the schedule specified in the respective arm.
Trial: NCT03726879
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered as per the schedule specified in the respective arm.
Trial: NCT03726879
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab will be administered as per the schedule specified in the respective arm.
Trial: NCT03726879
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab will be administered as per the schedule specified in the respective arm.
Trial: NCT03726879
Drug: Trastuzumab Emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.
Trial: NCT02766478
Drug: Genistein
RxNorm normalized name: Genistein
DrugBank: Genistein (DB01645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genistein is a natural supplement that comes from soy. Genistein will be taken orally (30 mg twice daily) for 12 weeks.
Trial: NCT00498407
Drug: CP-4055
RxNorm normalized name: CP
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CP-4055 5 mg/mL for infusion, dose: 200 mg/m2/day, schedule: d1-5 q4, 30 minutes IV infusion
Trial: NCT04548219
Drug: Mirikizumab
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference and test formulations of mirikizumab administered as a SC injection.
Trial: NCT04451330
Drug: Doxycycline hyclate
RxNorm normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline hyclate delayed release 120 mg tablets was administered orally for 12 weeks.
Trial: NCT04451330
Drug: Trifarotene Vehicle
RxNorm normalized name: trifarotene
DrugBank: Trifarotene (DB12808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trifarotene 50 mcg/g vehicle cream was applied topically once daily on face for 12 weeks.
Trial: NCT00005819
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive cisplatin IV over 30 minutes on day 7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
Trial: NCT00005819
Drug: fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive oral fenretinide twice daily for 7 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Trial: NCT00005819
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients receive paclitaxel IV over 3 hours. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
Trial: NCT02235688
Drug: aldoxorubicin
RxNorm normalized name: Aldoxorubicin
DrugBank: Aldoxorubicin (DB06013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered at 170 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
Trial: NCT02235688
Drug: aldoxorubicin
RxNorm normalized name: Aldoxorubicin
DrugBank: Aldoxorubicin (DB06013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered at 250 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
Trial: NCT02235688
Drug: aldoxorubicin
RxNorm normalized name: Aldoxorubicin
DrugBank: Aldoxorubicin (DB06013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered at 350 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
Trial: NCT02235688
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00131885
Drug: Levonorgestrel
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel in a single oral dose
Trial: NCT02569008
Drug: Fluid challenge with Compound Sodium Lactate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.
Trial: NCT00262613
Drug: sodium pyruvate in 0.9% sodium chloride solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01832870
Drug: sipuleucel-T
RxNorm normalized name: Sipuleucel-T
DrugBank: Sipuleucel-T (DB06688)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01832870
Drug: ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00157703
Drug: G207
RxNorm normalized name: G207
DrugBank: G207 (DB05827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)
Trial: NCT00280956
Drug: natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03394287
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every two weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
Trial: NCT03394287
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 250mg will be taked daily/intermittent dosing until unacceptable toxic effects or disease progression or other termination criteria appeared.
Trial: NCT02173912
Drug: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference)
RxNorm normalized name: candesartan cilexetil 16 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between.
Trial: NCT00822458
Drug: vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT02627430
Drug: Hsp90 Inhibitor AT13387
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02627430
Drug: Talazoparib
RxNorm normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00279890
Drug: Topical SR-01
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02118012
Drug: Chlorcyclizine HCl
RxNorm normalized name: chlorcyclizine HCl
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorcyclizine HCl (75 mg twice daily)
Trial: NCT02118012
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RBV was dosed via a weight-based regimen of 1000 mg daily\<75 kg and 1200 mg daily ≥75 kg.
Trial: NCT01904682
Drug: Oral rigosertib
RxNorm normalized name: Rigosertib
DrugBank: Rigosertib (DB12146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.
Trial: NCT01341262
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-120 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 200 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 200 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200
Trial: NCT01341262
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * INDUCTION THERAPY: 40 mg/d days 1-4, 9-12 and 17-20 (cycles 1 and 3, 30 days each); 40 mg/d days 1-4 (cycles 2 and 4, 30 days each)~* AFTER PBSC COLLECTION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)
Trial: NCT01341262
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 200 mg/sqm on day -1 for first and second ASCT
Trial: NCT03129074
Drug: Varlitinib
RxNorm normalized name: Varlitinib
DrugBank: Varlitinib (DB05944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: everyday
Trial: NCT01822808
Drug: Hydralazine
RxNorm normalized name: Hydralazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydralazine and placebo will be supplied as 25mg identical tablets and given at a dosage of 75mg/day up to week 4, thereafter 150mg/day up to week 24.
Trial: NCT03893097
Drug: Praziquantel
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/kg at baseline
Trial: NCT01822808
Drug: Isosorbide Dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate and placebo will be supplied as 10mg identical tablets and given at a dosage of 30mg/day up to week 4, thereafter 60mg/day up to week 24.
Trial: NCT03893097
Drug: Artesunate + Mefloquine
RxNorm normalized name: artesunate and mefloquine
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4mg/kg artesunate and 8 mg/kg mefloquine at baseline (3 consecutive days) and repeated at Week 6 and Week 12
Trial: NCT00501475
Drug: NAC Bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00289263
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04075331
Drug: Mepolizumab
RxNorm normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mepolizumab 100mg subcutaneous injection
Trial: NCT02363283
Drug: Glembatumumab Vedotin
RxNorm normalized name: Glembatumumab vedotin
DrugBank: Glembatumumab vedotin (DB05996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03208179
Drug: dihydroartemisinin-piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin placebo
Trial: NCT03208179
Drug: sulphadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women randomised to this intervention will receive stat dose of 3 tablets of 500 mg sulphadoxine and 25 mg of pyrimethamine each (total dose of 1,500mg sulphadoxine and 75mg pyrimethamine) on a single day of clinic visit
Trial: NCT03578172
Drug: human menopausal gonadotrophin
RxNorm normalized name: Human menopausal gonadotrophin
DrugBank: Menotropins (DB00032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental group:Women will be given HMG 37.5-150IU daily followed by monitoring of the follicular growth (folliculometry) when serum Estradiol (E2)\<100pg/ml，progesterone (P)\<1ng/ml. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle ≥20mm in diameter followed by luteal phase support (using progesterone supplements) after 24 hours.